FDA Accepts Supplemental New Drug Application (sNDA) for DALVANCE® (dalbavancin)

By: via Benzinga
Allergan plc (NYSE: AGN) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Allergan's supplemental New ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.